Victory Capital Management Inc. Has $841,000 Position in Myriad Genetics, Inc. (NASDAQ:MYGN)

Victory Capital Management Inc. increased its stake in shares of Myriad Genetics, Inc. (NASDAQ:MYGN) by 6.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 61,341 shares of the company’s stock after purchasing an additional 3,711 shares during the quarter. Victory Capital Management Inc. owned approximately 0.07% of Myriad Genetics worth $841,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the stock. Charles Schwab Investment Management Inc. boosted its holdings in shares of Myriad Genetics by 3.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,125,535 shares of the company’s stock worth $15,431,000 after purchasing an additional 42,233 shares during the period. Fisher Asset Management LLC boosted its holdings in shares of Myriad Genetics by 50.2% during the fourth quarter. Fisher Asset Management LLC now owns 905,209 shares of the company’s stock worth $12,410,000 after purchasing an additional 302,367 shares during the period. Illinois Municipal Retirement Fund boosted its holdings in shares of Myriad Genetics by 7.3% during the fourth quarter. Illinois Municipal Retirement Fund now owns 54,323 shares of the company’s stock worth $745,000 after purchasing an additional 3,706 shares during the period. Bank of New York Mellon Corp raised its position in Myriad Genetics by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 646,003 shares of the company’s stock valued at $8,857,000 after acquiring an additional 2,256 shares in the last quarter. Finally, Y Intercept Hong Kong Ltd raised its position in Myriad Genetics by 36.7% during the fourth quarter. Y Intercept Hong Kong Ltd now owns 52,667 shares of the company’s stock valued at $722,000 after acquiring an additional 14,134 shares in the last quarter. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on MYGN shares. Leerink Partners lowered shares of Myriad Genetics from an “outperform” rating to a “market perform” rating and cut their price objective for the company from $30.00 to $21.00 in a research report on Monday, December 9th. Raymond James reaffirmed an “outperform” rating and set a $19.00 price objective (down previously from $27.00) on shares of Myriad Genetics in a research report on Tuesday, February 25th. Stephens reaffirmed an “equal weight” rating and set a $20.00 price objective on shares of Myriad Genetics in a research report on Thursday, January 16th. StockNews.com lowered shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research report on Thursday, March 13th. Finally, Bank of America cut their price objective on shares of Myriad Genetics from $13.00 to $11.00 and set an “underperform” rating on the stock in a research report on Monday, March 3rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $21.89.

Myriad Genetics Trading Down 0.2 %

NASDAQ:MYGN opened at $9.91 on Friday. Myriad Genetics, Inc. has a 12 month low of $9.36 and a 12 month high of $29.30. The firm has a market cap of $904.87 million, a price-to-earnings ratio of -7.62 and a beta of 1.79. The company has a quick ratio of 1.73, a current ratio of 1.90 and a debt-to-equity ratio of 0.05. The company’s 50 day moving average is $12.23 and its 200-day moving average is $17.30.

Myriad Genetics (NASDAQ:MYGN) last released its quarterly earnings results on Tuesday, February 25th. The company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.12). The firm had revenue of $210.60 million during the quarter, compared to the consensus estimate of $210.35 million. Myriad Genetics had a negative net margin of 14.09% and a negative return on equity of 4.51%. During the same period in the prior year, the business earned ($0.12) EPS. Equities analysts anticipate that Myriad Genetics, Inc. will post -0.3 EPS for the current year.

Myriad Genetics Company Profile

Myriad Genetics, Inc, a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer.